Management

  • Shaun D. McMeans

    Senior Vice President of Finance, Administration and Chief Financial Officer
    Mr. McMeans has served as our Chief Financial Officer since February 2012, and as our Senior Vice President of Finance & Administration since February 2018. He previously was our Vice President of Finance & Administration from February 2012 until February 2018. Prior to joining us, Mr. McMeans was Vice President – Finance of Securaplane Technologies, Inc., a product supply company and division of Meggitt PLC, an aerospace, defense and energy conglomerate, from May 2011 to February 2012. Mr. McMeans was a financial consultant from February 2008 to April 2011, working both in an individual capacity and as a partner for Tatum LLC, a consulting company. Prior to February 2008, Mr. McMeans was Chief Financial Officer for The Long Companies, a full service residential and commercial real estate division of Berkshire Hathaway, Inc. Mr. McMeans also worked for over five years at LXU Healthcare, Inc., a manufacturer and distributor of specialty surgical equipment, as Controller and then Chief Financial and Operating Officer. In his early career, Mr. McMeans worked in roles of increasing responsibility, including Director of Finance, for Burnham Holdings, Inc., formerly Burnham Corporation, a manufacturer and distributor of residential and commercial hydronic heating equipment. Mr. McMeans received his B.S. in Accounting from The Pennsylvania State University.
    • John L. Lubniewski

      President & CEO
      Mr. Lubniewski has served as our Chief Executive Officer and as a member of our Board of Directors since April 2019 and previously served as our President and Chief Operating Officer since April 2018. Prior to this he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche in March 2008. From August 2010 to April 2011, Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010, Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years at Corning, Inc., a manufacturing company, in a variety of divisional, sector and corporate sales and marketing roles. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University. 
      • Sam M. Rua Jr.

        Senior Vice President of Regulatory Affairs and Quality Systems
        Mr. Rua has served as our Senior Vice President of Regulatory Affairs and Quality Systems since February 2018. Previously he served as our Vice President of Regulatory Affairs and Quality Systems from November 2011 until February 2018. He directs the quality systems organization as well as global regulatory and clinical affairs. Prior to joining us, Mr. Rua served in a variety of quality and regulatory roles with increasing responsibilities, most recently with Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of RTD, where he successfully led initiatives for PMA approvals and clearances for multiple IVD and companion diagnostic tests. Mr. Rua also was the Vice President of Global Regulatory and Clinical Affairs at Beckman Coulter from 2007 - 2010, and Executive Director of Quality and Regulatory at Third Wave Technologies, Inc. (now Hologic) from 2004-2007. While at Third Wave, he led the regulatory and clinical strategies for the Invader® UGT1A1 test and the Invader® HPV test. Mr. Rua received a B.S. in microbiology from the University of Arizona.
        • Maureen Cronin, SVP, CSO

          Senior Vice President and Chief Scientific Officer
          Maureen’s career spans 30 years in biotechnology research and product development and in drug discovery research. Most recently, Maureen served as Executive Director of Research Informatics at Celgene Corporation. Prior to that, she held increasingly senior roles at several biotechnology or molecular diagnostics startups, including service as a senior research executive at two leading oncology precision medicine diagnostics companies. She was part of the startup team at Genomic Health, Inc. in 2001, lead development of the OncotypeDX® test and rose to Vice President of Research.   She joined Foundation Medicine, Inc. as Senior Vice President of Research and Development in 2010 to lead the development of the FoundationOne® test.  Her technology research and development career began at Affymetrix where she led microarray technology assay development. She received her doctorate in physiology and pharmacology from University of California, San Diego as a Regents’ Fellow and completed a UCSD post-doctoral fellowship at the San Diego VA Hospital. She has been named an inventor on 36 U.S. and European patents and has authored or coauthored more than 40 peer reviewed publications. Her work at diagnostics and drug development gives her unique expertise and experience in developing and delivering precision medicine clinical diagnostics tests.